Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2-Restricted T Cell Epitopes.
Hoppes, R., Oostvogels, R., Luimstra, J.J., Wals, K., Toebes, M., Bies, L., Ekkebus, R., Rijal, P., Celie, P.H., Huang, J.H., Emmelot, M.E., Spaapen, R.M., Lokhorst, H., Schumacher, T.N., Mutis, T., Rodenko, B., Ovaa, H.(2014) J Immunol 193: 4803-4813
- PubMed: 25311806 
- DOI: 10.4049/jimmunol.1400800
- Primary Citation of Related Structures:  
4WJ5 - PubMed Abstract: 
Virus or tumor Ag-derived peptides that are displayed by MHC class I molecules are attractive starting points for vaccine development because they induce strong protective and therapeutic cytotoxic T cell responses. In thus study, we show that the MHC binding and consequent T cell reactivity against several HLA-A*02 restricted epitopes can be further improved through the incorporation of nonproteogenic amino acids at primary and secondary anchor positions ...